TherapeuticsMD, Inc. TXMD

TXMD Company Overview

TherapeuticsMD, Inc. (formerly Nasdaq: TXMD) is a women’s healthcare company focused on developing and commercializing prescription therapies for menopause-related conditions and reproductive health. The company historically operated within the biopharmaceutical and specialty pharmaceutical industries, with a concentration on hormone therapy products designed for women experiencing menopausal symptoms. Its principal commercial products included BIJUVA for moderate-to-severe vasomotor symptoms associated with menopause and IMVEXXY for moderate-to-severe dyspareunia resulting from menopause. The company also previously commercialized ANNOVERA, a long-acting reversible contraceptive vaginal system that was later licensed to another pharmaceutical partner.

TherapeuticsMD evolved from a women’s health supplement and pharmaceutical development business into a specialty pharmaceutical company centered on FDA-approved hormone therapies. The company pursued a strategy of developing products utilizing bio-identical hormone combinations and proprietary delivery technologies aimed at addressing unmet needs in women’s healthcare. In 2022, the company entered into a merger transaction with an affiliate of EW Healthcare Partners, after which TherapeuticsMD ceased trading as a publicly listed company. Prior to the transaction, the company’s operations and financial disclosures were publicly reported through SEC filings, including annual reports and investor presentations.